Research programme: pain therapeutics and companion diagnostics - Genentech/Xenon PharmaceuticalsAlternative Names: XEN-907
Latest Information Update: 16 Jul 2016
At a glance
- Originator Xenon Pharmaceuticals
- Developer Genentech; Xenon Pharmaceuticals
- Class Diagnostic agents; Small molecules
- Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain